Zurcher Kantonalbank Zurich Cantonalbank Has $187,000 Stake in Liquidia Co. (NASDAQ:LQDA)

Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Liquidia Co. (NASDAQ:LQDA) by 43.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,708 shares of the company’s stock after acquiring an additional 5,669 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Liquidia were worth $187,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its position in Liquidia by 144.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after purchasing an additional 230,820 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Liquidia by 18.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock worth $2,496,000 after buying an additional 32,076 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Liquidia by 735.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock worth $1,402,000 after buying an additional 123,402 shares during the period. Sapient Capital LLC acquired a new position in Liquidia in the 3rd quarter valued at about $1,336,000. Finally, HighVista Strategies LLC bought a new position in Liquidia in the 2nd quarter valued at about $1,461,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LQDA. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. Bank of America lowered their price objective on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Finally, Scotiabank started coverage on shares of Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Insider Buying and Selling at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 8,053 shares of Liquidia stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $89,468.83. Following the transaction, the chief executive officer now owns 812,193 shares in the company, valued at $9,023,464.23. The trade was a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Michael Kaseta sold 3,892 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $43,240.12. Following the completion of the transaction, the chief financial officer now directly owns 311,076 shares of the company’s stock, valued at $3,456,054.36. This trade represents a 1.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,007 shares of company stock worth $245,780 over the last three months. Corporate insiders own 30.10% of the company’s stock.

Liquidia Trading Down 4.1 %

Shares of NASDAQ:LQDA opened at $11.01 on Monday. The stock has a market capitalization of $931.89 million, a PE ratio of -6.75 and a beta of 0.22. The firm has a 50 day moving average of $10.84 and a 200-day moving average of $11.29. Liquidia Co. has a 12 month low of $6.86 and a 12 month high of $16.99.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).